ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026)
ArriVent BioPharma (AVBP) reported Share-based Compensation of $82.0 million for Q1 2026, up 3510.74% on a YoY basis from $2.3 million in Q1 2025, and up 2445.0% sequentially from $3.2 million in Q4 2025.
ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Share-based Compensation data on file, last reported at $82.0 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 3510.74% year-over-year to $82.0 million; the trailing twelve-month figure through Mar 2026 stood at $82.0 million (up 1589.68% YoY), and the FY2025 full-year result was $37.6 million, up 295.79% from the prior year.
- Share-based Compensation rose to $82.0 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $216.0 million in Q3 2023 to a low of $166000.0 in Q1 2023.
- A 4-year average of $39.0 million and a median of $2.3 million in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation plunged 99.6% in 2024 and surged 3510.74% in 2026, its largest moves.
- Tracing AVBP's Share-based Compensation over 4 years: stood at $319000.0 in 2023, then surged by 198.12% to $951000.0 in 2024, then soared by 238.8% to $3.2 million in 2025, then jumped by 2445.0% to $82.0 million in 2026.
- Business Quant data shows AVBP's Share-based Compensation at $82.0 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | 82.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.00 Mn |
| Mar 31, 2026 | 82.00 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 951,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 865,000.00 |
| Sep 30, 2024 | 865,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Mar 31, 2024 | 625,000.00 |
| Mar 31, 2024 | 625,000.00 |
| Dec 31, 2023 | 319,000.00 |
| Dec 31, 2023 | 319,000.00 |